Study on Risankizumab for Ulcerative Colitis

Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis. Related Content:

• Monoclonal Antibody Risankizumab for Ulcerative Colitis
• Risankizumab for Ulcerative Colitis